Literature DB >> 1701948

Mutational analysis of the DNA polymerase and ribonuclease H activities of human immunodeficiency virus type 2 reverse transcriptase expressed in Escherichia coli.

A Hizi1, R Tal, S H Hughes.   

Abstract

We have constructed a plasmid that, when introduced into Escherichia coli, induces the synthesis of large quantities of a polypeptide with an apparent molecular weight of 68 kDa. The HIV-2 reverse transcriptase (RT) made in E. coli is soluble in bacterial extracts and possesses both RNA-dependent DNA polymerase and ribonuclease H (RNase H) activities typical of retroviral RTs. The HIV-2 RT expression clone was used to generate mutations in HIV-2 RT. There is a strong correlation between the effects of individual mutations on the DNA polymerase and RNase H activities. Mutations that profoundly affect the two catalytic functions are not clustered in any particular region of the polypeptide. Those few mutations that selectively affect either the RNase H or the DNA polymerase suggest that, like other retroviral RTs, the DNA polymerase is associated with the amino-terminal portion of HIV-2 RT and the RNase H with the carboxy-terminal portion. Genetically, the HIV-2 RT resembles the HIV-1 RT more closely than it resembles Moloney murine leukemia virus RT. The two catalytic functions of Moloney murine leukemia virus RT can be separately expressed in active form by molecular cloning; those of HIV-1 and HIV-2 RT cannot.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1701948     DOI: 10.1016/0042-6822(91)90038-d

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  13 in total

1.  Inhibition of the integrases of human immunodeficiency viruses type 1 and type 2 by reverse transcriptases.

Authors:  Iris Oz; Orna Avidan; Amnon Hizi
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

2.  The ribonuclease H activity of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2 is modulated by residue 294 of the small subunit.

Authors:  Z Sevilya; S Loya; N Adir; A Hizi
Journal:  Nucleic Acids Res       Date:  2003-03-01       Impact factor: 16.971

3.  Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1.

Authors:  P L Boyer; A L Ferris; S H Hughes
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

Review 4.  Antiretroviral drug resistance in human immunodeficiency virus type 2.

Authors:  Michel L Ntemgwa; Thomas d'Aquin Toni; Bluma G Brenner; Ricardo J Camacho; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

5.  Redesignation of the RNase D activity associated with retroviral reverse transcriptase as RNase H.

Authors:  Z Hostomsky; S H Hughes; S P Goff; S F Le Grice
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

Review 6.  Retroviral reverse transcriptases.

Authors:  Alon Herschhorn; Amnon Hizi
Journal:  Cell Mol Life Sci       Date:  2010-04-01       Impact factor: 9.261

7.  Mode of inhibition of HIV reverse transcriptase by 2-hexaprenylhydroquinone, a novel general inhibitor of RNA-and DNA-directed DNA polymerases.

Authors:  S Loya; A Rudi; Y Kashman; A Hizi
Journal:  Biochem J       Date:  1997-06-15       Impact factor: 3.857

8.  Reverse transcriptase of mouse mammary tumour virus: expression in bacteria, purification and biochemical characterization.

Authors:  R Taube; S Loya; O Avidan; M Perach; A Hizi
Journal:  Biochem J       Date:  1998-02-01       Impact factor: 3.857

9.  Sulphydryl groups in the template-primer-binding domain of murine leukaemia virus reverse transcriptase. Identification and functional analysis of cysteine-90.

Authors:  S Basu; A Basu; M J Modak
Journal:  Biochem J       Date:  1993-12-15       Impact factor: 3.857

10.  Mutational analysis of the fingers domain of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  P L Boyer; A L Ferris; S H Hughes
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.